Homocysteine in Acute Coronary Syndrome
Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05125419
Collaborator
(none)
100
5.9
Study Details
Study Description
Brief Summary
This study aims to determine the relation between high homocysteine levels and increased incidence of acute coronary syndrome in young patients
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Cross sectional study to:
assess homocysteine level in young adult patients presenting with acute coronary syndrome
Study Design
Study Type:
Observational [Patient Registry]
Anticipated Enrollment
:
100 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Serum Homocysteine Level in the Setting of Acute Coronary Syndrome in Young Adult Patients
Anticipated Study Start Date
:
Nov 30, 2021
Anticipated Primary Completion Date
:
May 30, 2022
Anticipated Study Completion Date
:
May 30, 2022
Outcome Measures
Primary Outcome Measures
- Coronary care unit admission with acute coronary syndrome [From date of randomization up to 1 month]
Acute coronary syndrome hospitalization and cardiovascular deathes and estimated hazard ratios (HR) by use of multivariable Cox regression models
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
- The patients who presented in the hospital with chest pain consistent with acute coronary syndrome with any of the following features:
-
Electrocardiogram (ECG) changes:
-
ST elevation
-
ST depression
-
T wave inversion
-
recent left bundle branch block
- Troponin T elevation (Norma value < 0.06)
2- Age: -Between 18- 40 years (Group A) - Age > 40 years (Group B)
Exclusion Criteria:
-
Chest pain not consistent with acute coronary syndrome
-
Chronic kidney disease (CKD)
-
Rheumatic heart disease (RHD)
-
Congenital heart disease
-
Anemia
-
Cancer
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sohag University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
Mahmoud Abdelnasser Labib,
Principal investigator,
Sohag University
ClinicalTrials.gov Identifier:
NCT05125419
Other Study ID Numbers:
- Homocysteine level
First Posted:
Nov 18, 2021
Last Update Posted:
Nov 29, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: